1 Guidance

1 Guidance

1.1 Golimumab is recommended as an option for the treatment of active and progressive psoriatic arthritis in adults only if:

1.2 When using the Psoriatic Arthritis Response Criteria (PsARC; as set out in NICE technology appraisal guidance 199), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC and make any adjustments they consider appropriate.

  • National Institute for Health and Care Excellence (NICE)